Characteristic | |
---|---|
Demographic | |
Age, yrs, mean ± SD | 52.1 ± 14.2 |
White, n (%) | 299 (81) |
Other, n (%) | 70 (19) |
Female sex, n (%) | 265 (72) |
Current smoker, n (%) | 70 (19) |
Ex-smoker, n (%) | 165 (45) |
Never smoked, n (%) | 134 (36) |
Clinical | |
Symptom duration, mo, mean ± SD | 6.3 ± 3.2 |
TJC in 28 joints | 8.4 ± 6.5, 7 (10) |
TJC in 68 joints | 12.8 ± 9.3, 11 (12) |
SJC in 28 joints | 8.1 ± 6.1, 6 (9) |
SJC in 66 joints | 10.3 ± 8.0, 8 (11) |
PtGA, cm (0–10 cm scale) | 5.7 ± 2.9, 6 (5) |
PhGA, cm (0–10 cm scale) | 5.2 ± 2.4, 5 (4) |
DAS28 score | 5 ± 1.5, 5.1 (2.1) |
CDAI score | 27.3 ± 14.6, 25 (11.3) |
SDAI score | 28.3 ± 15, 26.7 (12) |
M-HAQ score, mean ± SD | 1.0 ± 0.7 |
Erosive disease | 94 (31)* |
Laboratory | |
ESR, mm/h | 27.3 ± 22.3, 20 (19.3) |
CRP, mg/l | 1.4 ± 1.8, 0.65 (1.6) |
RF-positive, n (%) | 223 (63)** |
ACPA-positive, n (%) | 198 (70)† |
Treatment initiated within first 3 mo, n (%) | |
No DMARD | 7 (2) |
Use of MTX alone | 48 (13) |
Use of non-MTX DMARD | 40 (11) |
Use of combination therapy (MTX or LEF ± SSZ ± HCQ) | 280 (76) |
Use of biologic agent | 22 (6) |
Use of oral glucocorticoid | 113 (31) |
↵* Data available for 301 patients.
↵** Data available for 355 patients.
↵† Data available for 283 patients. ACPA: anticitrullinated protein antibodies; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score 28 joints using ESR; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; HCQ: hydroxychloroquine; IQR: interquartile range; LEF: leflunomide; M-HAQ: modified Health Assessment Questionnaire; MTX: methotrexate; PhGA: physician global assessment of disease; PtGA: patient global assessment of disease; RF: rheumatoid factor; SDAI: Simplified Disease Activity Index; SJC: swollen joint count; SSZ: sulfasalazine; TJC: tender joint count; VAS: visual analog scale.